Avelumab significantly improved NK cell-mediated cytotoxicity against triple-negative breast cancer cells and tumor cells expressing higher levels of PD-L1 were shown to be more sensitive to avelumab-mediated ADCC. Here, CD274 is linked to neoplasm.